Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report

Cipla India business chief executive officer Nikhil Chopra said that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing.

|Jul 09, 2020, 10:41:08 IST

Bengaluru: Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at Rs 4,000 ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.Cipla had earlier said pricing would not exceed Rs 5,000. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.Cipla India business chief executive officer and executive vice president Nikhil Chopra said in an emailed statement that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing or dosage.The drug will be available through the government and hospitals only, the company said.Sources said the first batch of 10,000 vials had been printed with a price of Rs 4,000, Rs 800 below the cheapest option, launched by European competitor Mylan this week.Privately held Hetero Labs Ltd's version, Covifor, costs Rs 5,400 per vial while Mylan prices Desrem at Rs 4,800.CNBC TV-18 reported on Wednesday that Cipla was set to launch its drug in the next couple of days, priced at Rs 4,000.With coronavirus cases growing, several more of the big India-based healthcare firms which make much of the world’s pharmaceuticals are expected to launch competing versions of Remdesivir, the only major treatment so far approved for COVID-19.Remdesivir’s developer, Gilead Sciences Inc, has priced the original version at $390 per 100 mg vial for wealthier nations while signing licensing deals with generic producers to make the treatment widely available.India is now the third worst hit nation in the pandemic with 700,000 cases, behind the United States and Brazil.An employee at Cipla, who declined to be named because he is not authorized to speak to the media, said the company would send Cipremi to stockists starting Thursday.It was not immediately clear how many of Cipla's vials would be required for a full treatment course. Gilead has said a patient would typically need six vials of Remdesivir for a five-day course.

Stroke in young adults, silent symptoms and late diagnosis: India's growing brain health challenge

Neurologists warn that stroke is increasingly affecting people in their 30s and 40s, while many brain disorders progress silently before symptoms appear. They say early diagnosis, timely referrals and healthier lifestyles are key to reducing India's growing neurological disease burden.

5 min read

Brain tumours aren't always fatal, but delayed diagnosis can be: Experts explain the key warning signs

Brain tumours are frequently mistaken for common headaches, stress or age-related cognitive changes. Doctors say recognising warning signs early and adopting a brain-healthy lifestyle can improve outcomes and reduce the risk of long-term neurological complications.

2 min read

Spices, health and the Indian plate: Why chilli can be good for you—but moderation is still key

From boosting metabolism to supporting heart health, chillies offer several surprising health benefits. But experts say the amount you eat matters, and too much spice can do more harm than good.

4 min read

Organ donation: 5 myths you need to stop believing, according to a transplant specialist

Organ donation has the power to transform and save lives, but this can happen only when myths are replaced with facts. Building awareness, having open conversations and understanding the process can help families make informed decisions.

2 min read

Fish over meat: Why a pescatarian diet may help people with obesity live longer

A large UK study tracking over 150,000 adults with clinical obesity found pescatarians outlived regular meat-eaters, while vegetarians and vegans saw no similar benefit, but experts say the findings don't translate simply to Indian diets.